Apr 20, 2023 / 04:45PM GMT
Gil Blum - Needham & Company - Moderator
Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham Healthcare Conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, and I cover the immuno-oncology subsector. It is my pleasure to have with me today, Steven Kelly, the President and CEO of Carisma. (Conference Instructions) And with that, Steven, please go ahead.
Steven Kelly - Carisma Therapeutics Inc. - President, CEO
Great. Thanks, Gil. Really appreciate the opportunity to be at your conference and appreciate the opportunity to talk for a few minutes about Carisma and give you a flavor of what we're working on.
So Carisma is the world's leader in engineered myeloid cells. We have a really exciting platform. We have a pipeline of potential products, and we have a regular cadence of value inflection points as we as we look forward.
Our cell therapy platform really is a proprietary platform, takes all the traditional adoptive cell therapy tools and applies them with a
Carisma Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers